Entera Bio Ltd. appoints Riccardo Paolo Camisasca, M.D., as Chief Medical Officer ahead of EB613 Phase 3 initiation. CMO appointment strengthens leadership for pivotal EB613 phase 3 execution.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | 1 | — | 5 | 2 | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 11.02 | 8.66 | 14.88 | 18.43 |
| Receivables | — | 0.13 | — | — |
| Inventory | — | — | — | — |
| Other | 0.24 | 0.19 | 0.42 | 0.47 |
| 11.26 | 8.97 | 15.30 | 18.90 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 0.08 | 0.13 | 0.45 | 0.58 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 1.09 | 1.18 | 2.20 | 2.10 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | 0.04 | — | — | — |
0.04
|
| ’24 | — | 0.06 | 0.04 | 0.08 |
0.18
|
| ’22 | 0.07 | 0.04 | 0.01 | 0.01 |
0.13
|
| ’21 | 0.16 | 0.11 | 0.14 | 0.17 |
0.57
|
| ’20 | 0.04 | 0.05 | 0.05 | 0.22 |
0.37
|
| ’19 | — | 0.07 | 0.06 | 0.10 |
0.24
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.09) | (3.46) | — | — |
—
|
| ’25 | (1.40) | (1.63) | (2.50) | (1.83) |
(7.37)
|
| ’24 | (1.86) | (1.33) | (2.15) | (1.47) |
(6.82)
|
| ’23 | (1.61) | (1.56) | (1.52) | (2.62) |
(7.31)
|
| ’22 | (4.79) | (2.83) | (2.87) | (2.01) |
(12.50)
|
| ’21 | (2.32) | (2.12) | (2.11) | (2.51) |
(9.06)
|
| ’20 | (2.66) | (3.53) | (2.85) | (1.53) |
(10.56)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (3.09) | (3.47) | — | — |
—
|
| ’25 | (1.41) | (1.66) | (2.54) | (1.86) |
(7.48)
|
| ’24 | (1.86) | (1.33) | (2.15) | (1.47) |
(6.82)
|
| ’23 | (1.62) | (1.56) | (1.52) | (2.62) |
(7.33)
|
| ’22 | (4.81) | (2.85) | (2.87) | (2.01) |
(12.55)
|
| ’21 | (2.32) | (2.12) | (2.12) | (2.52) |
(9.08)
|
| ’20 | (2.68) | (3.53) | (2.87) | (1.53) |
(10.61)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.07) | (0.14) | — | — |
—
|
| ’25 | (0.06) | (0.06) | (0.07) | (0.07) |
(0.25)
|
| ’24 | (0.05) | (0.06) | (0.08) | (0.06) |
(0.25)
|
| ’23 | (0.08) | (0.08) | (0.08) | (0.07) |
(0.31)
|
| ’22 | (0.13) | (0.11) | (0.11) | (0.10) |
(0.45)
|
| ’21 | (0.43) | (0.19) | (0.05) | 0.21 |
(0.47)
|
| ’20 | (0.16) | (0.17) | (0.09) | (0.11) |
(0.55)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | 0.47 | 0.52 | 0.58 | 1.50 | — | — | — |
Low Price
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 3.51 | 1.48 | 3.35 | 3.22 | — | — | — |
High Price
|
| — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 20 | 19 | 20 | 22 | — | — | — |
Employees
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.01 | 0.00 | 0.01 | 0.00 | — | — | — |
Revenue/Emp
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.13 | — | 0.18 | 0.04 | ‡‡‡‡‡ | — | — |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 24.63% | — | 4.97% | 0.00% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.93) | (8.86) | (9.53) | (11.44) | — | — | — |
EBT
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9,652.24%) | 0.00% | (5,263.54%) | (27,235.71%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.07) | (8.89) | (9.54) | (11.44) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.06 | 0.06 | 0.05 | 0.03 | — | — | — |
Depreciation
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.45) | (0.31) | (0.25) | (0.25) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.43) | (0.25) | (0.18) | (0.16) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.44) | (0.25) | (0.18) | (0.16) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.41 | 0.36 | 0.21 | 0.28 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 28.81 | 29.01 | 37.65 | 46.19 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | — | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 219.28 | — | 409.32 | 401.84 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.50 | — | 9.88 | 6.84 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| — | — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 128.13 | — | 366.97 | 336.90 | ‡‡‡‡‡ | — | — |
EV/Sales
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.37) | — | (10.48) | (10.05) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.50) | (7.31) | (6.82) | (7.37) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.05) | (0.02) | 0.00 | (0.11) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.55) | (7.33) | (6.82) | (7.48) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.51 | 10.17 | 7.80 | 13.10 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.09 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (12.22) | (11.02) | (8.66) | (14.88) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.75 | 10.39 | 8.08 | 13.10 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (66.84%) | (71.42%) | (90.20%) | (90.13%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (76.17%) | (80.30%) | (103.34%) | (108.01%) | — | — | — |
ROE
|
Entera Bio Ltd. (ENTX), leveraging its proprietary Peptelligence platform for oral peptide delivery, is at a pivotal juncture in the burgeoning markets for osteoporosis, hypoparathyroidism, and GLP-1 therapies amid the obesity epidemic. Despite the hallmark volatility of clinical-stage biotechs—lumpy milestone revenues, escalating R&D losses projected to widen to -$34 million by 2026, and share dilution—the company’s disciplined operations shine through stable headcount, shrinking cash burn, and a cash-rich balance sheet. Recent revenue rebounds and gross margins hinting at scalable manufacturing potential echo historical biotech transitions from development to commercialization, much like peers riding oral semaglutide’s blockbuster wave.
Stock resilience stands out: trading at multi-year lows versus 2021 peaks, yet up 52% from 2022 troughs amid stabilizing fundamentals, with premiums in PS and EV/Sales multiples justified by pipeline promise. Insider confidence bolsters the case—CEO and directors scooped up over 95,000 shares at sub-$2 levels in late 2025-early 2026, with zero sells—signaling alignment ahead of key milestones.
Analyst unanimity points to ~570% upside, driven by Phase 3 topline data for EB613 (oral PTH for osteoporosis) in Q2 2026, potential partnerships tapping $1B+ markets, and GLP-1 expansion opportunities. In a sector prone to binary outcomes, Entera’s setup offers calculated asymmetry for patient investors, reminiscent of early disruptors in endocrine therapies—warranting a deeper dive into the catalysts ahead.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.